In the News
Feb 02, 2011
In July 2010, an advisory panel voted 12-1 to urge the FDA to withdraw the approved use of Avastin in metastatic HER2-negative breast cancer. As a result of this announcement, IntrinsiQ hypothesized that physicians would immediately decrease the use the drug in new patients. We also believed that physicians would continue the course of therapy in existing patients, drawing out the decline we would see in Avastin sales. In fact, within the first three months after the advisory panel’s announcement, the usage of Avastin dropped across all lines of therapy as physicians grew reluctant to prescribe the drug when choosing their next course of therapy.